阿达木单抗治疗中重度银屑病的PK/PD特征与治疗药物监测应用

杨建鑫 ,  俞蕴莉

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 921 -927.

PDF (465KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 921 -927. DOI: 10.12092/j.issn.1009-2501.2026.07.008
综述与讲座

阿达木单抗治疗中重度银屑病的PK/PD特征与治疗药物监测应用

作者信息 +

Pharmacokinetic/pharmacodynamic characteristics of adalimumab in moderate-to-severe psoriasis and its therapeutic drug monitoring applications

Author information +
文章历史 +
PDF (475K)

摘要

阿达木单抗作为全球首个获批上市的抗肿瘤坏死因子 α(tumor necrosis factor-α,TNF-α)单克隆抗体,已成为中重度银屑病的一线治疗选择。然而,该药物在银屑病患者群体中的药代动力学/药效动力学(pharmacokinetics/pharmacodynamics,PK/PD)特征尚未完全阐明。本文比较系统地综述了阿达木单抗在中重度银屑病治疗中的 PK 及其 PD 特性,重点探讨了抗药抗体形成和体质量等患者特异性因素对药物暴露的影响,并分析了治疗药物监测在银屑病治疗中的临床应用价值及优化策略,强调了建立银屑病特异性药物浓度-疗效关系模型和治疗窗的重要价值,以期为今后开展大样本临床研究提供明确方向,对银屑病个体化精准治疗策略的制定和实施提供指导。

Abstract

As the first anti-TNF-α monoclonal antibody approved for clinical use worldwide, adalimumab has become a first-line treatment for moderate-to-severe psoriasis. However, this drug's pharmacokinetic (PK) and pharmacodynamic (PD) characteristics in psoriasis patients have not yet been fully elucidated. This article systematically reviews the PK and PD properties of adalimumab in the treatment of moderate-to-severe psoriasis, with a focus on the impact of patient-specific factors such as anti-drug antibody formation and body weight on drug exposure. Additionally, it analyzes the clinical application value and optimization strategies of therapeutic drug monitoring (TDM) in psoriasis treatment. This review emphasizes the importance of establishing psoriasis-specific drug concentration-efficacy relationship models and therapeutic windows, aiming to provide clear directions for future large-scale clinical studies and to guide the development and implementation of personalized precision treatment strategies for psoriasis.

关键词

阿达木单抗 / 银屑病 / PK/PD / 治疗药物监测

Key words

adalimumab / psoriasis / PK/PD / therapeutic drug monitoring

引用本文

引用格式 ▾
杨建鑫,俞蕴莉. 阿达木单抗治疗中重度银屑病的PK/PD特征与治疗药物监测应用[J]. 中国临床药理学与治疗学, 2026, 31(7): 921-927 DOI:10.12092/j.issn.1009-2501.2026.07.008

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

刘迎春, 杨伟, 张晓东. 银屑病诱发因素及其共患病的研究进展[J].中国临床实用医学, 2023, 14(2): 77-80.

[2]

刘紫欣, 申琳. 生物制剂治疗银屑病的效果及安全性研究进展[J].中国医药导报, 2024, 21(30): 65-69,78.

[3]

中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂及小分子药物治疗指南 (2024 版)[J].中华皮肤科杂志, 2024, 57(11): 976-997.

[4]

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics[J].J Am Acad Dermatol, 2019, 80(4): 1029-1072.

[5]

Saeki H, Mabuchi T, Asahina A,et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)[J].J Dermatol, 2023, 50(2): e41-e68.

[6]

Wride AM, Chen GF, Spaulding SL, et al. Biologics for psoriasis[J].Dermatol Clin, 2024, 42(3): 339-355.

[7]

Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial[J].J Am Acad Dermatol, 2008, 58(1): 106-115.

[8]

Wang W, Wang EQ, Balthasar JP.Monoclonal antibody pharmacokinetics and pharmacodynamics[J].Clin Pharmacol Ther, 2008, 84(5): 548-558.

[9]

No DJ, Inkeles MS, Amin M, et al. Drug survival of biologic treatments in psoriasis: a systematic review[J].J Dermatolog Treat, 2018, 29(5): 460-466.

[10]

Belinchon Romero I, Mateu Puchades A, Ribera Pibernat M, et al. Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review[J].Ann Med, 2023, 55(1): 1335-1345.

[11]

Wcislo-Dziadecka D, Zbiciak-Nylec M, Brzezinska-Wcislo L, et al. TNF-alpha in a molecularly targeted therapy of psoriasis and psoriatic arthritis[J].Postgrad Med J, 2016, 92(1085): 172-178.

[12]

Rodriguez-Fernandez K, Mangas-Sanjuan V, Merino-Sanjuan M, et al. Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis[J].Pharmaceutics, 2022, 14(3): 654.

[13]

European Medicines Agency. Humira: summary of product characteristics[EB/OL]. (2021-07-26)[2024-01-17].https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf

[14]

Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions[J].Clin Exp Immunol, 1994, 96(1): 146-151.

[15]

U. S. Food and Drug Administration. Clinical pharmacology biopharmaceutics review(s) for Amjevita (adalimumab-atto)[EB/OL]. (2016-09-23)[2024-01-17].https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000ClinPharmR.pdf

[16]

Menting SP, van Lumig PP, de Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up[J].JAMA Dermatol, 2014, 150(2): 130-136.

[17]

Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis[J].N Engl J Med, 2021, 385(2): 130-141.

[18]

Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial[J].Ann Rheum Dis, 2020, 79(1): 123-131.

[19]

Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis[J].Br J Clin Pharmacol, 2015, 79(2): 286-297.

[20]

Mostafa NM, Nader AM, Noertersheuser P, et al. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis[J].J Eur Acad Dermatol Venereol, 2017, 31(3): 490-497.

[21]

van Huizen A, Bank P, van der Kraaij G, et al. Quantifying the effect of methotrexate on adalimumab response in psoriasis by pharmacokinetic-pharmacodynamic modeling[J].J Invest Dermatol, 2024, 144(4): 794-801.

[22]

Greenzaid J, Feldman S. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of moderate-to-severe psoriasis[J].Clin Pharmacokinet, 2024, 63(2): 137-153.

[23]

Hsu L, Armstrong AW.Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response[J].Expert Rev Clin Immunol, 2013, 9(10): 949-958.

[24]

Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease[J].Gastroenterology, 2020, 158(1): 189-199.

[25]

van der Kraaij G, Busard C, van den Reek J, et al. Adalimumab with methotrexate vs. Adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized controlled trial[J].J Invest Dermatol, 2022, 142(9): 2375-2383.

[26]

Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study[J].Br J Dermatol, 2010, 163(2): 402-411.

[27]

Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study[J].Inflamm Bowel Dis, 2015, 21(4): 783-792.

[28]

Smolen JS, Taylor PC, Tanaka Y, et al. Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis[J].Rheumatology (Oxford), 2024, 63(11): 3015-3024.

[29]

丁肖梁, 缪丽燕. 基于治疗药物监测优化阿达木单抗治疗: 当前证据和展望[J].中国循证医学杂志, 2023, 23(1): 85-93.

[30]

Assa A, Matar M, Turner D, et al. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring[J].Gastroenterology, 2019, 157(4): 985-996.

[31]

Papamichael K, Juncadella A, Wong D, et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease[J].J Crohns Colitis, 2019, 13(8): 976-981.

[32]

Kawano-Dourado L, Kristianslund EK, Zeraatkar D, et al. Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline[J].BMJ, 2024, 387: e079830.

[33]

Raharja A, Arkir Z, Rinaldi G, et al. Real-world implementation and outcomes of adalimumab therapeutic drug monitoring in psoriasis: a national specialized center experience[J].J Invest Dermatol, 2023, 143(9): 1708-1716.

[34]

中国炎症性肠病诊疗质控评估中心, 中华医学会消化病学分会炎症性肠病学组. 生物制剂治疗炎症性肠病专家建议意见[J].中华炎性肠病杂志, 2021, 5(3): 193-206.

[35]

Stamp LK, Keating P, Frampton C, et al. Relationship between adalimumab concentrations, antidrug antibodies, and disease activity in rheumatoid arthritis: a cross-sectional observational study[J].J Rheumatol, 2024, 51(3): 242-249.

[36]

Dehoorne JL, Groth H, Carlé E, et al. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment[J].Pediatr Rheumatol Online J, 2023, 21(1): 148.

[37]

Menting SP, Coussens E, Pouw MF, et al. Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment[J].JAMA Dermatol, 2015, 151: 616-622.

基金资助

国家自然科学基金面上项目(82173879)

苏州市姑苏卫生人才青年拔尖人才项目(GSWS2022040)

苏州大学附属第二医院学科建设托举项目(XKTJ-XK202406)

苏州大学附属第二医院科研预研基金(SDFEYBS2308)

苏州市重点实验室建设项目(SZS2025012)

AI Summary AI Mindmap
PDF (465KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉